About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

Leadership Team

Andrew Fadden
Chief Business Officer
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer and Head of Translational Science
Joseph Dukes
Chief Scientific Officer

Board of Directors

Scientific Advisory Board

Joseph Dukes

Chief Scientific Officer

Joe joined Enara Bio in 2019 following leadership across research and early development of novel immunotherapies, having led molecules from early discovery and validation through to first-in-human clinical studies.

Prior to joining Enara Bio, Joe spent eight years at Immunocore, developing novel TCR-based bispecific therapeutics. During this time, he established a bespoke, in vitro preclinical approach for generating safety data to de-risk TCR-based therapeutics. In his role as Head of Biology, Joe oversaw TCR discovery, characterisation, and preclinical screening of drug candidates. In addition, Joe was Program Leader for the second TCR-bispecific molecule to enter the clinic, leading cross-functional teams from early discovery in research, through preclinical and clinical development to successful IND/CTA submissions and first-in-human Phase 1 studies.

Joe obtained a PhD in Cell Biology and a subsequent post-doctoral fellowship at The University of Bath.